2月2日，悦康药业跌5.15%，截至发稿，报23.01元/股，成交9003.05万元，换手率0.85%，总市值103.55 亿元。悦康药业股价已经连续5天下跌，区间累计跌幅10.64%。 资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号,香港铜锣湾希慎道 33号利园1期19楼1919室，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康 药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药 物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑 肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未 来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料 药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。 从悦康药业十大流通股东角度 易方达医疗保健行业混合A（110023）基金经理为杨桢霄。 截至发稿，杨桢霄累计任职时间9年169天，现 ...

公司2024年末对产品"银杏叶提取物注射液"价格及销售策略进行调整，该事项对公司收入和利润呈现阶 段性较大的影响。公司坚持长期发展战略，不断调整和完善经营策略，提升运营效率，同时逐步优化销 售策略，维护核心销售渠道的稳定，持续增强公司核心竞争力和投资价值。报告期内，公司继续保持高 比例研发投入，研发费用同比上升，高比例的研发投入对公司净利润产生了一定影响。 智通财经APP讯，悦康药业(688658.SH)发布2025年年度业绩预亏公告，预计2025年年度实现归属于母 公司所有者的净利润为-28,000万元到-23,500万元，与上年同期(法定披露数据)相比，将出现亏损。 ...

根据公告，业绩变动系2024年末对产品"银杏叶提取物注射液"价格及销售策略进行调整，同时，报告期 内，研发费用同比上升，对净利润产生了一定影响。 北京商报讯（记者 王寅浩 宋雨盈）1月30日，悦康药业发布2025年业绩预告，预计2025年归属于母公司 所有者的净亏损为2.35亿—2.8亿元，与上年同期相比，将出现亏损。预计归属于母公司所有者扣除非经 常性损益后的净亏损为2.6亿—3.05亿元。 ...

每经AI快讯，悦康药业1月30日晚间发布业绩预告，悦康药业集团股份有限公司预计2025年年度实现归 属于母公司所有者的净利润为-2.8亿元到-2.35亿元，与上年同期相比，将出现亏损。业绩变动主要原因 是，公司2024年末对产品"银杏叶提取物注射液"价格及销售策略进行调整，该事项对公司收入和利润呈 现阶段性较大的影响。公司坚持长期发展战略，不断调整和完善经营策略，提升运营效率，同时逐步优 化销售策略，维护核心销售渠道的稳定，持续增强公司核心竞争力和投资价值。公司坚定将研发创新置 于战略核心地位，持续积极推动新药研发项目。报告期内，公司继续保持高比例研发投入，研发费用同 比上升，高比例的研发投入对公司净利润产生了一定影响。 （记者 曾健辉） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 ...

悦康药业集团股份有限公司 2026 年第一次临时股东会会议资料 悦康药业集团股份有限公司 2026 年第一次临时股东会 会议资料 2026 年 2 月 | | | 悦康药业集团股份有限公司 2026 年第一次临时股东会会议资料 悦康药业集团股份有限公司 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《公司法》《证券法》《上市公司股东会规则》以及《悦康 药业集团股份有限公司章程》（以下简称"《公司章程》"）的相关规定，认真做 好召开股东会的各项工作，特制定本须知： 一、为保证股东会的严肃性和正常秩序，切实维护股东的合法权益，除出席 会议的股东及股东代表、董事、公司高级管理人员、公司聘任律师及中介机构外， 公司有权依法拒绝其他人员入场。 二、请出席会议的股东及股东代表在会议召开前 20 分钟到达会议现场办理 签到手续。大会工作人员将对出席会议者的身份进行必要的核对工作，请被核对 者给予配合。 三、股东及股东代表参加股东会依法享有发言权、质询权、表决权等权利。 如股东及股东代表欲在本次股东会上发言，可在签到时先向大会工作人员进行登 记。会 ...

证券代码：688658 证券简称：悦康药业 公告编号：2026-003 悦康药业集团股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1.经财务部门初步测算，悦康药业集团股份有限公司（以下简称"公司"）预 计 2025 年年度实现归属于母公司所有者的净利润为-28,000.00 万元到-23,500.00 万元，与上年同期（法定披露数据）相比，将出现亏损。 2.预计 2025 年年度实现归属于母公司所有者扣除非经常性损益后的净利润 为-30,500.00 万元到-26,000.00 万元。 （三）公司本次业绩预告情况未经注册会计师审计。 二、上年同期业绩情况 （一）2024 年度，利润总额为：15,235.76 万元 归属于母公司所有者的净利润：12,371.70 万元 （二）公司坚定将研发创新置于战略核心地位，持续积极推动新药研发项目。 报告期内，公司 ...

悦康药业公告称，预计2025年年度归属于母公司所有者的净利润为-2.80亿元到-2.35亿元，上年同期为 1.24亿元；扣非净利润为-3.05亿元到-2.60亿元，上年同期为1.11亿元。业绩预亏主要因2024年末对"银 杏叶提取物注射液"价格及销售策略调整，对收入和利润产生阶段性较大影响，且报告期内研发费用同 比上升。具体数据以最终审计结果为准。 ...

2026年1月初，科创板上市的化学药企悦康药业集团股份有限公司(688658.SH)，已正式向港交所递交了H股上市申请。 港股医药板块即将迎来一位处境微妙的"老朋友"。2026年1月初，科创板上市的化学药企悦康药业集团股份有限公司(688658.SH)，已正式向港交所递交了 H股上市申请。这标志着其筹划多时的"A+H"双平台上市战略进入实质性阶段。公司董事会早在2025年12月初就通过了相关议案，并确定了上市方案的大 体框架。 此番南下，由中信证券等机构保驾护航，其目标不仅是搭建一个国际化的融资平台。对于正处于核心产品价格体系重塑、业绩连续下滑的悦康药业而言， 此次港股IPO更具现实意义——它被视为一场为"研发创新"与"补充营运资金"的关键"输血"。然而，在投资者眼中，这份"A+H"的故事背后，承载的更多 是公司寻求渡过眼前困境的迫切需求。 | [編纂]的[編纂]數目 : [編纂]股Ｈ股(視乎[編纂] | | | --- | --- | | 行使與否而定) | | | . . 「編纂]股H股(可予重新分配) | [編纂]數目 | | . . 「編纂」股H股(可予重新分配及 | [編纂]數目 | | 視乎[编纂 ...

Core Viewpoint - The Hong Kong stock market is set to welcome Yuyuan Pharmaceutical Group Co., Ltd. as it officially submitted its H-share listing application to the Hong Kong Stock Exchange, marking a significant step in its dual-platform listing strategy [1][3]. Group 1: Company Overview - Yuyuan Pharmaceutical, listed on the STAR Market, aims to establish an international financing platform through its H-share listing, which is crucial for its research and development innovation and operational funding [3]. - The company has faced significant challenges, including a decline in revenue and profitability, with revenue dropping from 4.542 billion yuan in 2022 to 3.781 billion yuan in 2024, and net profit plummeting from 335 million yuan to 124 million yuan in the same period [6]. Group 2: Financial Performance - The company recorded a net loss of 49.27 million yuan in the first quarter of 2025, indicating ongoing financial difficulties [6]. - The decline in performance is primarily attributed to the price reduction of its flagship product, Ginkgo Biloba Extract Injection, which saw a price drop of approximately 53% due to regulatory scrutiny, leading to a quarterly loss of 86.01 million yuan in Q4 2024 [6]. Group 3: Business Structure and Challenges - Yuyuan Pharmaceutical's heavy reliance on a single product has weakened its risk resilience, with the Ginkgo product historically contributing nearly 60% of its revenue [7]. - The transition from generic drugs to innovative drugs has been slow, with only one new drug launched and several research projects delayed [7]. - The company has incurred high sales expenses, totaling 7.37 billion yuan from 2021 to 2024, raising concerns about its sales model and compliance [7]. Group 4: Market Sentiment and Investment Considerations - Investors are weighing the potential for a turnaround against ongoing risks, with the company's future performance heavily dependent on its ability to stabilize and innovate [9][10]. - The H-share fundraising is intended for R&D and operational support, which could alleviate financial pressures and revitalize stalled projects [10]. - The dual-listing structure may provide a valuation anchor and enhance liquidity, although the H-share price is expected to be at a discount to the A-share price [10]. Group 5: Upcoming IPO Details - The IPO timeline is yet to be announced, with the application currently under review [13]. - The total amount to be raised and the share price range are still pending, with the issuance expected to not exceed 15% of the total share capital post-issue [13]. - The presence of cornerstone investors will be a key indicator of market confidence in the company's recovery prospects [13].

Core Viewpoint - The pharmaceutical sector is experiencing significant capital inflow, driven by the emergence of Nipah virus cases in India, which has heightened interest in vaccines and innovative drugs, alongside the continuous expansion of Chinese pharmaceutical companies in overseas markets [1] Group 1: Market Dynamics - On January 26, the pharmaceutical sector saw a notable increase in capital inflow, with market sentiment becoming more active due to multiple factors, including marginal improvements in industry fundamentals and supportive policies [1] - The emergence of overseas pandemic events, such as Nipah virus infections, has reignited market focus on vaccines, antiviral drugs, and public health defense systems, reinforcing long-term investment confidence in the pharmaceutical sector, particularly in innovative drugs, vaccines, and diagnostics [1] Group 2: Structural Opportunities - Recent institutional insights indicate that structural opportunities within the pharmaceutical sector are becoming clearer, with the strong momentum of innovative drugs continuing to be a core driver of the sector [1] - By January 2026, several companies, including Yilian Biotech and Rongchang Biotech, have achieved licensing agreements, validating the global competitiveness of Chinese innovative drugs, especially in cutting-edge technology areas like ADC, bispecific antibodies, and small nucleic acids [1] Group 3: Sector Developments - Progress in specific subfields is enhancing confidence in the sector, with small nucleic acid drugs showing positive clinical data in chronic hepatitis B and metabolic diseases, attracting accelerated investments from leading domestic and international companies [2] - Breakthroughs in oral immunomodulatory drugs targeting new pathways provide new treatment options for difficult diseases such as psoriasis and ulcerative colitis, warranting ongoing monitoring of related domestic companies' clinical advancements [2] - The GLP-1 class products maintain high demand in the weight loss and diabetes markets, with a gradually forming domestic pricing system and rapid overseas market expansion opening up further growth opportunities [2] Group 4: Investment Strategies - Institutions suggest investors focus on the following main lines for pharmaceutical sector investments: - Concentrate on cutting-edge areas of innovative drugs, particularly in the accelerating overseas expansion of bispecific antibodies, ADC, and small nucleic acids, such as YK Pharma and Sunlight Novo [3] - Capitalize on innovative breakthroughs in tumor therapeutic vaccines [3] - Invest in the CXO and research service industry chain that supports innovative research and development, such as Yinos and Zhaoyan New Drug [3] - Pay attention to traditional Chinese medicine and pharmacy sectors with overseas potential or high dividend defensive attributes, such as Zoli Pharmaceutical, Dong'e Ejiao, and Yifeng Pharmacy [3]